Document is current

Any future updates will be listed below

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

Crossref DOI link: https://doi.org/10.1186/s12885-016-2635-0

Published Online: 2016-08-02

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark